NCNA - NuCana plc

2.16
0.200   9.255%

Share volume: 96,835
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$1.96
0.20
0.10%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
18%
Profitability 18%
Dept financing 2%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.47%
1 Month
-4.00%
3 Months
-47.83%
6 Months
-25.26%
1 Year
142.70%
2 Year
-73.82%
Key data
Stock price
$2.16
P/E Ratio 
0.00
DAY RANGE
$2.00 - $2.21
EPS 
-$0.01
52 WEEK RANGE
$0.03 - $7.22
52 WEEK CHANGE
$168.32
MARKET CAP 
9.673 M
YIELD 
N/A
SHARES OUTSTANDING 
2.643 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-15-2025
BETA 
2.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$37,784
AVERAGE 30 VOLUME 
$36,381
Company detail
CEO: Hugh S. Griffith
Region: US
Website: nucana.com
Employees: 30
IPO year: 2017
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

NuCana plc engages in the development of products for the treatment of cancer. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil.

Recent news